Inhalable Antibiotic Delivery Using a Dry Powder Co-delivering Recombinant Deoxyribonuclease and Ciprofloxacin for Treatment of Cystic Fibrosis
- 763 Downloads
To achieve efficient antibiotic delivery to the cystic fibrosis (CF) airway using a single inhalable powder co-encapsulating a mucolytic and an antibiotic.
Inhalable dry powders containing deoxyribonuclease and/or ciprofloxacin (DNase, Cipro, and DNase/Cipro powders) were produced by spray-drying with dipalmitylphosphatidylcholine, albumin, and lactose as excipients, and their antibacterial effects were evaluated using the artificial sputum model.
All powders showed mass median aerodynamic diameters below 5 µm. Both drugs were loaded in the dry powders without loss in quantity and activity. Dry powders containing DNase significantly decreased the storage modulus of the artificial sputum medium in less than 30 min. When applied to artificial sputum laden with Pseudomonas aeruginosa, Cipro/DNase powder showed better antibacterial activity than Cipro powder. The higher activity of the Cipro/DNase powder is attributable to the mucolytic activity of DNase, which promotes penetration of the dry powder into the artificial sputum and efficient dissolution and diffusion of ciprofloxacin.
Inhalational delivery of antibiotics to the CF airway can be optimized when the sputum barrier is concomitantly addressed. Co-delivery of antibiotics and DNase using an inhalable particle system may be a promising strategy for local antipseudomonal therapy in the CF airway.
KEY WORDSartificial sputum co-delivery cystic fibrosis DNase inhalable dry powder
This research was supported by the Cystic Fibrosis Foundation (Yeo), 3M Non-tenured Faculty Grant (Yeo), and the China Scholarship Council (Y. Yang).
- 1.Orenstein DM, Rosenstein BJ, Stern RC. Diagnosis of Cystic Fibrosis. Cystic Fibrosis Medical Care. Philadelphia: Lippincott Williams and Wilkins; 2000. p. 21–53.Google Scholar
- 2.Genetic Testing for Cystic Fibrosis. NIH Consens Statement Online. 1997;15:1–37.Google Scholar
- 4.Murphy TM, Rosenstein BJ. Advances in the science and treatment of cystic fibrosis lung diseases: A continuing medical education resource, Duke University Medical Center & Health System, Durham, North Carolina.Google Scholar
- 6.Cotran RS, Kumar V, Collins T, Robbins SL. Robbins pathologic basis of disease. Philadelphia: Saunders; 1999.Google Scholar
- 17.Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard—Eighth edition (M07-A8); 2009.Google Scholar
- 21.Cipolla DC, Gonda I, Meserve KC, Weck S, Shire SJ. Formulation and aerosol delivery of recombinant deoxyribonucleac-acid derived human deoxyribonuclease-I. In: Cleland JLLR (ed.) Symposium on Formulation and Delivery of Proteins and Peptides, at the 205th National Meeting of the American-Chemical-Society. Denver, Co; 1993. pp. 322–42.Google Scholar
- 27.Ghani M, Soothill JS. Ceftazidime, gentamicin, and rifampicin, in combination, kill biofilms of mucoid Pseudomonas aeruginosa. Can J Microbiol. 1997;43.Google Scholar
- 31.Hodson ME, Geddes DM, Bush A. Cystic fibrosis. London: Hodder Arnold; 2007.Google Scholar
- 33.Tomkiewicz R, Kishore C, Freeman J, Rubin B. DNA and actin filament ultrastructure in cystic fibrosis sputum. In: Baum G, Priel Z, Roth Y, Liron N, Ostield E, editors. Cilia, Mucus, and Mucociliary Interactions. New York: Marcel Dekker Inc; 1998. p. 333–41.Google Scholar
- 44.Pearson J. Inhalation Technologies—A Breath of Fresh Air. Drug Delivery Report. 2006;19–21. Spring/Summer).Google Scholar
- 49.The United States Pharmacopeia: The National Formulary (USP32/NF27), The United States Pharmacopeial Convention, 2009.Google Scholar
- 54.Sung JC, Padilla DJ, Garcia-Contreras L, Verberkmoes JL, Durbin D, Peloquin CA, Elbert KJ, Hickey AJ, Edwards DA. Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems for Pulmonary Delivery. Pharm Res. 2009.Google Scholar
- 61.Tsifansky MD, Yeo Y, Evgenov OV, Bellas E, Benjamin J, Kohane DS. Microparticles for Inhalational Delivery of Antipseudomonal Antibiotics. AAPS J. 2008.Google Scholar